Cost-Effectiveness of Tirzepatide Versus Liraglutide, Both Adjunct to Diet and Exercise, for Patients with Obesity or Overweight: A UK Perspective.

ABSTRACT:

Introduction

This study estimated the cost-effectiveness from a UK healthcare system perspective of tirzepatide (5 mg, 10 mg, 15 mg) compared to liraglutide (3 mg) both adjunct to a reduced-calorie diet and increased physical activity in patients with a body mass index (BMI) ≥ 30 kg/m² (obesity), or with a BMI ≥ 27 to < 30 kg/m² (overweight) + ≥ 1 obesity-related complication ('trial population'). A subgroup analysis was performed in liraglutide's National Institute of Health and Care Excellence (NICE) recommended population (patients with a BMI of ≥ 35 kg/m² with non-diabetic hyperglycaemia and a high risk of cardiovascular disease [CVD]).

Methods

A lifetime simulation model evaluated the costs and long-term clinical outcomes of each treatme

SUBMITTER: Capehorn M 

PROVIDER: S-EPMC12474619 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature